FY2025 EPS Forecast for Theratechnologies Lifted by Analyst

Theratechnologies Inc. (TSE:TH) – Equities research analysts at Leede Financial increased their FY2025 EPS estimates for Theratechnologies in a report released on Wednesday, December 4th. Leede Financial analyst D. Loe now expects that the company will post earnings of $0.10 per share for the year, up from their prior forecast of $0.09. The consensus estimate for Theratechnologies’ current full-year earnings is $0.03 per share. Leede Financial also issued estimates for Theratechnologies’ FY2026 earnings at $0.31 EPS.

Theratechnologies Price Performance

Shares of TH stock opened at C$2.07 on Thursday. The company has a market capitalization of C$95.18 million, a P/E ratio of -11.11, a P/E/G ratio of -8.50 and a beta of 1.73. The company’s 50-day simple moving average is C$1.73 and its two-hundred day simple moving average is C$1.79. Theratechnologies has a one year low of C$1.59 and a one year high of C$3.43. The company has a debt-to-equity ratio of 562.07, a current ratio of 1.10 and a quick ratio of 0.64.

Theratechnologies (TSE:TH) last announced its quarterly earnings data on Thursday, October 10th. The company reported C$0.09 EPS for the quarter. Theratechnologies had a negative return on equity of 1,116.86% and a negative net margin of 8.47%. The company had revenue of C$30.96 million for the quarter.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.